← Oncology Approval Tracker

FDA DECISION ·

Akeega + prednisone

niraparib + abiraterone acetate + prednisone · Janssen Biotech

FDA approvalNew therapyProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with metastatic castration-resistant prostate cancer with a deleterious or suspected deleterious BRCA alteration on an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

A fixed-dose PARP inhibitor and androgen-synthesis inhibitor combination addressed a BRCA-selected population.

What research teams should watch

Confirm the specific BRCA result and monitor the hematologic and endocrine requirements of the combined regimen.

PRIMARY RECORDS

Sources